8.1 Collaborative Practice Agreements & Medication Therapy Management

8.1 Collaborative Practice Agreements & Medication Therapy Management

Quick Answer: Minnesota embeds advanced clinical pharmacy in Minn. Stat. §151.01, subd. 27. Pharmacists may initiate, manage, modify, and discontinue drug therapy under a written protocol or collaborative practice agreement (CPA) with authorized practitioners (clause (7)). A CPA is a written, signed agreement (subds. 27b–27c). Therapy changes must be documented in the medical record or reported to a practitioner responsible for the patient. Separate statutory prescriptive authorities under §151.37, subds. 14–17 (covered in §8.2) do not replace CPA/protocol rules for general drug-therapy management.

NABP Area 2 — Pharmacist Practice (33%) includes administration and therapy management. On the Minnesota MPJE, that means knowing the difference between (1) ordinary dispensing under a prescription, (2) therapy management under a protocol/CPA, and (3) limited pharmacist prescribing under Board protocols in §151.37. This section builds the protocol/CPA foundation and the broad practice-of-pharmacy map.

Practice of Pharmacy: The Advanced-Care Map

§151.01, subd. 27 is not a marketing slogan—it is the legal inventory of acts that constitute pharmacy practice. High-yield advanced-practice clauses include:

Exam reflex: If a vignette says a pharmacist “adjusted warfarin” or “started an ACE inhibitor,” ask: Was there a patient-specific Rx from a practitioner, a protocol/CPA, or a specific §151.37 Board-protocol authority? Minnesota does not give pharmacists general independent authority to prescribe any legend drug for any condition without one of those legal hooks.

Protocol vs Collaborative Practice Agreement

Minnesota defines three related terms carefully:

Protocol (§151.01, subd. 27a)

A protocol is a specific written plan that either:

1. Describes the nature and scope of activities a pharmacist may engage in when initiating, managing, modifying, or discontinuing drug therapy as allowed in subd. 27, clause (7); or
2. Authorizes a pharmacist to administer vaccines and complies with subd. 27, clause (6).

Protocols are written and specific. Vague “use your judgment” understandings are not exam-safe answers.

Collaborative practice (§151.01, subd. 27b)

Collaborative practice means patient-care activities, consistent with subd. 27, engaged in by one or more pharmacists who have agreed to work in collaboration with one or more practitioners to initiate, manage, and modify drug therapy under specified conditions mutually agreed to by the pharmacists and practitioners.

Collaborative practice agreement (§151.01, subd. 27c)

A collaborative practice agreement is a written and signed agreement between one or more pharmacists and one or more practitioners that allows the pharmacist(s) to engage in collaborative practice.

Memorize the formalities: written + signed + mutual conditions. Oral hallway agreements fail the definition.

Who May Be on the Other Side of a Protocol/CPA?

Under subd. 27, clause (7), therapy initiation/management/modification/discontinuation may proceed according to a written protocol or CPA between:

(i) one or more pharmacists and one or more dentists, optometrists, physicians, physician assistants, podiatrists, or veterinarians; or

(ii) one or more pharmacists and one or more physician assistants authorized under ch. 147A, or advanced practice registered nurses authorized under §148.235.

The partner must be a practitioner class the statute recognizes for that collaboration. Do not invent authority to enter a CPA with an unlicensed coach, medical assistant, or out-of-scope professional.

For mental-illness IM/SC administration under clause (5)(ii), the protocol/CPA partner list again ties to dentists, optometrists, physicians, PAs, podiatrists, veterinarians, or APRNs authorized to prescribe/dispense/administer under §148.235—and changes must still be documented or reported.

Documentation and Reporting Duties

Statute repeats a bright-line duty for protocol/CPA therapy changes (clause (7) and parallel language in clause (5)):

Any changes in drug therapy made pursuant to a protocol or collaborative practice agreement must be documented by the pharmacist in the patient’s medical record or reported by the pharmacist to a practitioner responsible for the patient’s care.

MPJE stems often hide this duty in operational detail: the pharmacist adjusts therapy correctly under a CPA but never documents or reports. That is a compliance miss even if the clinical decision was protocol-compliant.

Medication Therapy Management in Minnesota Law Language

“MTM” is common clinical shorthand; the statute speaks in practice-of-pharmacy and protocol/CPA terms. For exam purposes, MTM-style services typically map to:

1. Participation in clinical interpretation and monitoring of drug therapy (clause (3))
2. Drug regimen reviews and related selection activities (clause (4))
3. Initiation, management, modification, and discontinuation of therapy under protocol/CPA (clause (7))
4. CLIA-waived testing used to support monitoring, with therapy changes still tethered to protocol/CPA when initiating/modifying/discontinuing therapy (clause (3))
5. Patient counseling on therapeutic values, content, hazards, and uses (clause (9))—layered with Rule 6800.0910 counseling standards taught elsewhere

CLIA-waived testing trap: A pharmacist may order and perform waived tests and may delegate administration of the test to a technician or intern under direct supervision. That is not freestanding authority to rewrite chronic regimens outside a protocol/CPA. Therapy initiation/modification/discontinuation remains protocol/CPA-bound under clause (3).

How Protocol/CPA Relates to §151.37 Prescribing

Do not collapse frameworks:

§151.37 subdivisions themselves state that nothing in those prescribing authorities prohibits participation in protocol/CPA therapy management under §151.01, subd. 27. Both can coexist; they answer different legal questions.

Practitioner Definition Cross-Link

§151.01, subd. 23 defines practitioner (physicians, osteopathic physicians licensed to practice medicine, dentists, optometrists, podiatrists, veterinarians, APRNs, certified midwives, PAs, with limited expansions for dental therapists and—for certain sections—pharmacists authorized under §151.37 subds. 14–17). When a CPA refers to “practitioners,” use the statutory definition, not a casual list of “anyone with a white coat.”

Study Checklist

1. Quote that CPA = written + signed agreement enabling collaborative practice (27c).
2. List eligible protocol/CPA partners under clause (7).
3. State the document or report duty after therapy changes.
4. Keep CLIA-waived testing separate from freestanding full prescribing.
5. Distinguish CPA therapy management from §151.37 Board-protocol prescribing.
6. Map advanced-practice facts to Area 2 study time.

Next: master the four §151.37 pharmacist prescribing lanes—contraception, nicotine replacement, acute-overdose opiate antagonists, and HIV prevention.